According to documents submitted by Eli Lilly Pharmaceuticals of the United States to the US Securities and Exchange Commission, as of October 13, 2026, the company held 19.9% of TREX BIO's shares.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.